2018 is here. Now get ready for ‘market-defining’ I-O readouts
admin 2nd January 2018 Uncategorised 0If you thought 2017 was a game-changer for immuno-oncology, just wait. In the first half of 2018 alone, each of the four major players—Merck, Bristol-Myers Squibb, Roche and AstraZeneca—is expecting a phase 3 data readout that Bernstein analyst Tim Anderson says will be “market-defining.”
More: 2018 is here. Now get ready for ‘market-defining’ I-O readouts
Source: fierce